FDA confirms PROACT 1 Phase 3 may support full approval; Q3 cash $406.8M

PROKIDNEY CORP.

FDA Type B meeting confirms PROACT 1 Phase 3 could be sufficient for BLA; accelerated approval pathway available using eGFR slope as surrogate endpoint.
Cash, equivalents and marketable securities $406.8M at Sept 30, 2024, expected to fund operations into 2027.
Q3 2024 net loss before noncontrolling interest $41.1M vs $42.0M in Q3 2023; R&D $31.3M, G&A $17.7M including $5.3M impairment.
Presented five posters at ASN Kidney Week including Phase 2 REGEN-007 late-breaking data.
Shares outstanding: 291,661,950 Class A and B ordinary shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.